Generic Name: Lithium carbonate
Dosage Form: tablet, capsule, oral solution

Lithium CARBONATE Tablets USP, Lithium CARBONATE Capsules USP, Lithium Oral Solution USP

Rx only

Warning

Lithium toxicity is closely related to serum Lithium levels, and can occur at doses close to therapeutic levels. Facilities for prompt and accurate serum Lithium determinations should be available before initiating therapy (see DOSAGE AND ADMINISTRATION).

Slideshow: Can Prescription Drugs Lead to Weight Gain?

Lithium Description

Each tablet for oral administration contains:

Lithium Carbonate . . . . . . . . . . 300 mg

Each capsule for oral administration contains:

Lithium Carbonate . . . . . . . . . . 150 mg, 300 mg or 600 mg

Each 5 mL of solution for oral administration contains:

Lithium ion (Li+) . . . . . . . . . . 8 mEq

(equivalent to amount of Lithium in 300 mg of Lithium carbonate), alcohol 0.3% v/v.

Inactive Ingredients

The tablets contain calcium stearate, microcrystalline cellulose, povidone, sodium lauryl sulfate, and sodium starch glycolate. The capsules contain FD&C Red No. 40, gelatin, sodium lauryl sulfate, talc, titanium dioxide, and the imprinting ink contains FD&C Blue No. 2, FD&C Yellow No. 6, FD&C Red No. 40, iron oxide, polyvinly pyrrolidone, shellac. The solution contains citric acid, raspberry blend, sodium benzoate, sorbitol and water.

Lithium Oral Solution is a palatable oral dosage form of Lithium ion. It is prepared in solution from Lithium hydroxide and citric acid in a ratio approximately di-Lithium citrate.

Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94, and an emission line at 671 nm on the flame photometer.

The empirical formula for Lithium Citrate is C65Li3O7; molecular weight 209.92. Lithium acts as an antimanic.

Lithium Carbonate is a white, light, alkaline powder with molecular formula Li2CO3 and molecular weight 73.89.

Lithium - Clinical Pharmacology

Preclinical studies have shown that Lithium alters sodium transport in nerve and muscle cells and effects a shift toward intraneuronal metabolism of catecholamines, but the specific biochemical mechanism of Lithium action in mania is unknown.

Indications and Usage for Lithium

Lithium is indicated in the treatment of manic episodes of Bipolar Disorder. Bipolar Disorder, Manic (DSM-III) is equivalent to Manic Depressive illness, Manic, in the older DSM-II terminology.

Lithium is also indicated as a maintenance treatment for individuals with a diagnosis of Bipolar Disorder. Maintenance therapy reduces the frequency of manic episodes and diminishes the intensity of those episodes which may occur.

Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness, and possibly hostility. When given to a patient experiencing a manic episode, Lithium may produce a normalization of symptomatology within 1 to 3 weeks.

Contraindications

Lithium should generally not be given to patients with significant renal or cardiovascular disease, severe debilitation or dehydration, or sodium depletion, and to patients receiving diuretics, since the risk of Lithium toxicity is very high in such patients. If the psychiatric indication is life-threatening, and if such a patient fails to respond to other measures, Lithium treatment may be undertaken with extreme caution, including daily serum Lithium determinations and adjustment to the usually low doses ordinarily tolerated by these individuals. In such instances, hospitalization is a necessity.

Warnings

Lithium toxicity is closely related to serum Lithium levels, and can occur at doses close to therapeutic levels (see DOSAGE AND ADMINISTRATION).

Unmasking of Brugada Syndrome

There have been postmarketing reports of a possible association between treatment with Lithium and the unmasking of Brugada Syndrome. Brugada Syndrome is a disorder characterized by abnormal electrocardiographic (ECG) findings and a risk of sudden death. Lithium should generally be avoided in patients with Brugada Syndrome or those suspected of having Brugada Syndrome. Consultation with a cardiologist is recommended if: (1) treatment with Lithium is under consideration for patients suspected of having Brugada Syndrome or patients who have risk factors for Brugada Syndrome, e.g., unexplained syncope, a family history of Brugada Syndrome, or a family history of sudden unexplained death before the age of 45 years, (2) patients who develop unexplained syncope or palpitations after starting Lithium therapy.

Pregnancy

Lithium may cause fetal harm when administered to a pregnant woman. There have been reports of Lithium having adverse effects on nidations in rats, embryo viability in mice, and metabolism in-vitro of rat testis and human spermatozoa have been attributed to Lithium, as have teratogenicity in submammalian species and cleft palates in mice. Studies in rats, rabbits and monkeys have shown no evidence of Lithium-induced teratology. Data from Lithium birth registries suggest an increase in cardiac and other anomalies, especially Ebstein’s anomaly. If the patient becomes pregnant while taking Lithium, she should be apprised of the potential risk to the fetus. If possible, Lithium should be withdrawn for at least the first trimester unless it is determined that this would seriously endanger the mother.

Lithium-Induced Renal Effects

Chronic Lithium therapy may be associated with diminution of renal concentrating ability, occasionally presenting as nephrogenic diabetes insipidus, with polyuria and polydipsia. Such patients should be carefully managed to avoid dehydration with resulting Lithium retention and toxicity. This condition is usually reversible when Lithium is discontinued.

Morphologic changes with glomerular and interstitial fibrosis and nephron-atrophy have been reported in patients on chronic Lithium therapy. Morphologic changes have also been seen in bipolar patients never exposed to Lithium. The relationship between renal functional and morphologic changes and their association with Lithium therapy has not been established.

When kidney function is assessed, for baseline data prior to starting Lithium therapy or thereafter, routine urinalysis and other tests may be used to evaluate tubular function (e.g., urine specific gravity or osmolality following a period of water deprivation, or 24-hour urine volume) and glomerular function (e.g., serum creatinine or creatinine clearance). During Lithium therapy, progressive or sudden changes in renal function, even within the normal range, indicate the need for reevaluation of treatment.

Precautions

General

The ability to tolerate Lithium is greater during the acute manic phase and decreases when manic symptoms subside (see DOSAGE AND ADMINISTRATION).

The distribution space of Lithium approximates that of total body water. Lithium is primarily excreted in urine with insignificant excretion in feces. Renal excretion of Lithium is proportional to its plasma concentration. The half-life of elimination of Lithium is approximately 24 hours. Lithium decreases sodium reabsorption by the renal tubules which could lead to sodium depletion. Therefore, it is essential for the patient to maintain a normal diet, including salt, and an adequate fluid intake (2500-3000 mL) at least during the initial stabilization period. Decreased tolerance to Lithium has been reported to ensue from protracted sweating or diarrhea and, if such occur, supplemental fluid and salt should be administered.

In addition to sweating and diarrhea, concomitant infection with elevated temperatures may also necessitate a temporary reduction or cessation of medication.

Previously existing underlying thyroid disorders do not necessarily constitute a contraindication to Lithium treatment; where hypothyroidism exists, careful monitoring of thyroid function during Lithium stabilization and maintenance allows for correction of changing thyroid parameters, if any. Where hypothyroidism occurs during Lithium stabilization and maintenance, supplemental thyroid treatment may be used.

Information for the Patients

A condition known as Brugada Syndrome may pre-exist and be unmasked by Lithium therapy. Brugada Syndrome is a heart disorder characterized by abnormal electrocardiographic (ECG) findings and risk of sudden death. Patients should be advised to seek immediate emergency assistance if they experience fainting, lightheadedness, abnormal heart beats, or shortness of breath.

Outpatients and their families should be warned that the patient must discontinue Lithium therapy and contact his physician if such clinical signs of Lithium toxicity as diarrhea, vomiting, tremor, mild ataxia, drowsiness, or muscular weakness occur.

Lithium may impair mental and/or physical abilities. Caution patients about activities requiring alertness (e.g., operating vehicles or machinery).

Drug Interactions

Combined Use of Haloperidol and Lithium.

An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leucocytosis, elevated serum enzymes, BUN and FBS) followed by irreversible brain damage has occurred in a few patients treated with Lithium plus haloperidol. A causal relationship between these events and the concomitant administration of Lithium and haloperidol has not been established; however, patients receiving such combined therapy should be monitored closely for early evidence of neurological toxicity and treatment discontinued promptly if such signs appear.

The possibility of similar adverse interactions with other antipsychotic medication exists.

Lithium may prolong the effects of neuromuscular blocking agents. Therefore, neuromuscular blocking agents should be given with caution to patients receiving Lithium.

Caution should be used when Lithium and diuretics or angiotensin converting enzyme (ACE) inhibitors are used concomitantly because sodium loss may reduce the renal clearance of Lithium and increase serum Lithium levels with risk of Lithium toxicity. When such combinations are used, the Lithium dosage may need to be decreased, and more frequent monitoring of Lithium plasma levels is recommended.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)

Lithium levels should be closely monitored when patients initiate or discontinue NSAID use. In some cases, Lithium toxicity has resulted from interactions between an NSAID and Lithium. Indomethacin and piroxicam have been reported to increase significantly steady-state plasma Lithium concentrations. There is also evidence that other nonsteroidal anti-inflammatory agents, including the selective cyclooxygenase-2 (COX-2) inhibitors, have the same effect. In a study conducted in healthy subjects, mean steady-state Lithium plasma levels increased approximately 17% in subjects receiving Lithium 450 mg BID with celecoxib 200 mg BID as compared to subjects receiving Lithium alone.

Pregnancy, Teratogenic Effects

Pregnancy Category D:

See WARNINGS section.

Nursing Mothers

Lithium is excreted in human milk. Nursing should not be undertaken during Lithium therapy except in rare and unusual circumstances where, in the view of the physician, the potential benefits to the mother outweigh possible hazards to the child.

Usage in Children

Since information regarding the safety and effectiveness of Lithium in children under 12 years of age is not available, its use in such patients is not recommended at this time. There has been a report of a transient syndrome of acute dystonia and hyperreflexia occurring in a 15 kg child who ingested 300 mg of Lithium carbonate.

Adverse Reactions

Lithium Toxicity

The likelihood of toxicity increases with increasing serum Lithium levels. Serum Lithium levels greater than 1.5 mEq/l carry a greater risk than lower levels. However, patients sensitive to Lithium may exhibit toxic signs at serum levels below 1.5 mEq/l.

Diarrhea, vomiting, drowsiness, muscular weakness and lack of coordination may be early signs of Lithium toxicity, and can occur at Lithium levels below 2.0 mEq/l. At higher levels, giddiness, ataxia, blurred vision, tinnitus and a large output of dilute urine may be seen. Serum Lithium levels above 3.0 mEq/l may produce a complex clinical picture involving multiple organs and organ systems. Serum Lithium levels should not be permitted to exceed 2.0 mEq/l during the acute treatment phase.

Fine hand tremor, polyuria and mild thirst may occur during initial therapy for the acute manic phase, and may persist throughout treatment. Transient and mild nausea and general discomfort may also appear during the first few days of Lithium administration.

These side effects are an inconvenience rather than a disabling condition, and usually subside with continued treatment or a temporary reduction or cessation of dosage. If persistent, a cessation of dosage is indicated.

The following adverse reactions have been reported and do not appear to be directly related to serum Lithium levels.

Neuromuscular: Tremor, muscle hyperirritability (fasciculations, twitching, clonic movements of whole limbs), ataxia, choreo-athetotic movements, hyperactive deep tendon reflexes.

Central Nervous System: Blackout spells, epileptiform seizures, slurred speech, dizziness, vertigo, incontinence of urine or feces, somnolence, psychomotor retardation, restlessness, confusion, stupor, coma, acute dystonia, downbeat nystagmus.

Cardiovascular: Cardiac arrhythmia, hypotension, peripheral circulatory collapse, sinus node dysfunction with severe bradycardia (which may result in syncope), unmasking of Brugada Syndrome (See WARNINGS: Unmasking of Brugada Syndrome and PRECAUTIONS: Information for the Patients).

Neurological: Cases of pseudotumor cerebri (increased intracranial pressure and papilledema) have been reported with Lithium use. If undetected, this condition may result in enlargement of the blind spot, constriction of visual fields and eventual blindness due to optic atrophy. Lithium should be discontinued, if clinically possible, if this syndrome occurs.

Gastrointestinal: Anorexia, nausea, vomiting, diarrhea.

Genitourinary: Albuminuria, oliguria, polyuria, glycosuria.

Dermatologic: Drying and thinning of hair, anesthesia of skin, chronic folliculitis, xerosis cutis, alopecia and exacerbation of psoriasis.

Autonomic Nervous System: Blurred vision, dry mouth.

Thyroid Abnormalities: Euthyroid goiter and/or hypothyroidism (including myxedema) accompanied by lower T3 and T4. Iodine 131 uptake may be elevated. (See PRECAUTIONS). Paradoxically, rare cases of hyperthyroidism have been reported.

EEG Changes: Diffuse slowing, widening of frequency spectrum, potentiation and disorganization of background rhythm.

EKG Changes: Reversible flattening, isoelectricity or inversion of T-waves.

Miscellaneous: Fatigue, lethargy, transient scotomata, dehydration, weight loss, tendency to sleep.

Miscellaneous Reactions Unrelated to Dosage are: Transient electroencephalographic and electrocardiographic changes, leucocytosis, headache, diffuse non-toxic goiter with or without hypothyroidism, transient hyperglycemia, generalized pruritus with or without rash, cutaneous ulcers, albuminuria, worsening of organic brain syndromes, excessive weight gain, edematous swelling of ankles or wrists, and thirst or polyuria, sometimes resembling diabetes insipidus, and metallic taste.

A single report has been received of the development of painful discoloration of fingers and toes and coldness of the extremities within one day of the starting of treatment of Lithium. The mechanism through which these symptoms (resembling Raynaud’s Syndrome) developed is not known. Recovery followed discontinuance.

Overdosage

The toxic levels for Lithium are close to the therapeutic levels. It is therefore important that patients and their families be cautioned to watch for early symptoms and to discontinue the drug and inform the physician should they occur. Toxic symptoms are listed in detail under ADVERSE REACTIONS.

Treatment

No specific antidote for Lithium poisoning is known. Early symptoms of Lithium toxicity can usually be treated by reduction of cessation of dosage of the drug and resumption of the treatment at a lower dose after 24 to 48 hours. In severe cases of Lithium poisoning, the first and foremost goal of treatment consists of elimination of this ion from the patient.

Treatment is essentially the same as that used in barbiturate poisoning: 1) gastric lavage, 2) correction of fluid and electrolyte imbalance and 3) regulation of kidney functioning. Urea, mannitol, and aminophylline all produce significant increases in Lithium excretion. Hemodialysis is an effective and rapid means of removing the ion from the severely toxic patient. Infection prophylaxis, regular chest X-rays, and preservation of adequate respiration are essential.

Lithium Dosage and Administration

Acute Mania

Optimal patient response to Lithium Carbonate usually can be established and maintained with 600 mg t.i.d. Optimal patient response to Lithium Oral Solution usually can be established and maintained with 10 mL (2 full teaspoons) (16 mEq of Lithium) t.i.d. Such doses will normally produce an effective serum Lithium level ranging between 1.0 and 1.5 mEq/l. Dosage must be individualized according to serum levels and clinical response. Regular monitoring of the patient’s clinical state and of serum Lithium levels is necessary. Serum levels should be determined twice per week during the acute phase, and until the serum level and clinical condition of the patient have been stabilized.

Long-Term Control

The desirable serum Lithium levels are 0.6 to 1.2 mEq/l. Dosage will vary from one individual to another, but usually 300 mg of Lithium Carbonate t.i.d. or q.i.d., or 5 mL (1 full teaspoon) (8 mEq of Lithium) of Lithium Oral Solution t.i.d. or q.i.d. will maintain this level. Serum Lithium levels in uncomplicated cases receiving maintenance therapy during remission should be monitored at least every two months.

Patients abnormally sensitive to Lithium may exhibit toxic signs at serum levels of 1.0 to 1.5 mEq/l. Elderly patients often respond to reduced dosage, and may exhibit signs of toxicity at serum levels ordinarily tolerated by other patients.

N.B.

Blood samples for serum Lithium determination should be drawn immediately prior to the next dose when Lithium concentrations are relatively stable (i.e., 8-12 hours after the previous dose). Total reliance must not be placed on serum levels alone. Accurate patient evaluation requires both clinical and laboratory analysis.

How is Lithium Supplied

Lithium Carbonate Tablets USP

300 mg white, scored tablets (Identified 54 452)

NDC 0054-8528-25: Unit dose, 10 tablets per strip, 10 strips per shelf pack, 10 shelf packs per shipper.

(For Institutional Use Only).

NDC 0054-4527-25: Bottles of 100 tablets.

NDC 0054-4527-31: Bottles of 1000 tablets.

Lithium Carbonate Capsules USP

150 mg white opaque colored capsules (size 4)

(Identified 54 213).

NDC 0054-8526-25: Unit dose, 10 capsules per strip, 10 strips per shelf pack, 10 shelf packs per shipper.

(For Institutional Use Only).

NDC 0054-2526-25: Bottles of 100 capsules.

300 mg flesh-colored capsules (size 2)

(Identified 54 463).

NDC 0054-8527-25: Unit dose, 10 capsules per strip, 10 strips per shelf pack, 10 shelf packs per shipper.

(For Institutional Use Only).

NDC 0054-2527-25: Bottles of 100 capsules.

NDC 0054-2527-31: Bottles of 1000 capsules.

600 mg white opaque/flesh colored capsules

(size 0) (Identified 54 702).

NDC 0054-8531-25: Unit dose, 10 capsules per strip, 10 strips per shelf pack, 10 shelf packs per shipper.

(For Institutional Use Only).

NDC 0054-2531-25: Bottles of 100 capsules.

Store and Dispense:

Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature]. Protect from moisture. Dispense in a tight container as defined in the USP/NF.

Lithium Oral Solution USP, 8 mEq per 5 mL.

NDC 0054-8529-04: Unit dose Patient Cup™ filled to deliver 5 mL, ten 5 mL Patient Cup™ per shelf pack, ten shelf packs per shipper.

(For Institutional Use Only).

NDC 0054-3527-63: Bottles of 500 mL.

Store and Dispense:

Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature]. Dispense in a tight container as defined in the USP/NF.

4055500//08

Revised October 2011

© RLI, 2011

 

Package Label - Lithium Carbonate Tablets USP

NDC 0054-8528-25: Unit dose

Rx Only

Roxane Laboratories, Inc.

NDC 0054-4527-25: Bottles of 100 tablets.

 

Package Label - Lithium Carbonate Capsules USP

NDC 0054-8526-25: Unit dose

NDC 0054-2526-25: Bottles of 100 capsules.

NDC 0054-8527-25: Unit dose

NDC 0054-2527-25: Bottles of 100 capsules.

NDC 0054-8531-25: Unit dose

NDC 0054-2531-25: Bottles of 100 capsules.

 

Package Label - Lithium Oral Solution USP, 8 mEq per 5 mL

NDC 0054-8529-04: Unit dose Patient Cup™

NDC 0054-3527-63: Bottles of 500 mL.

Lithium CARBONATE 
Lithium carbonate tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0054-8528
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Lithium CARBONATE (Lithium CATION) Lithium CARBONATE 300 mg
Inactive Ingredients
Ingredient Name Strength
CALCIUM STEARATE  
CELLULOSE, MICROCRYSTALLINE  
POVIDONE K29/32  
SODIUM LAURYL SULFATE  
SODIUM STARCH GLYCOLATE TYPE A POTATO  
Product Characteristics
Color WHITE Score 2 pieces
Shape ROUND Size 10mm
Flavor Imprint Code 54;452
Contains         
Packaging
# Item Code Package Description
1 NDC:0054-8528-25 10 TABLET in 1 BLISTER PACK
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA018558 06/14/1982
Lithium CARBONATE 
Lithium carbonate tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0054-4527
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Lithium CARBONATE (Lithium CATION) Lithium CARBONATE 300 mg
Inactive Ingredients
Ingredient Name Strength
CALCIUM STEARATE  
CELLULOSE, MICROCRYSTALLINE  
POVIDONE K29/32  
SODIUM LAURYL SULFATE  
SODIUM STARCH GLYCOLATE TYPE A POTATO  
Product Characteristics
Color WHITE Score 2 pieces
Shape ROUND Size 10mm
Flavor Imprint Code 54;452
Contains         
Packaging
# Item Code Package Description
1 NDC:0054-4527-25 100 TABLET in 1 BOTTLE
2 NDC:0054-4527-31 1000 TABLET in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA018558 01/29/1982
Lithium CARBONATE 
Lithium carbonate capsule, gelatin coated
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0054-8526
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Lithium CARBONATE (Lithium CATION) Lithium CARBONATE 150 mg
Inactive Ingredients
Ingredient Name Strength
FD&C RED NO. 40  
GELATIN  
SODIUM LAURYL SULFATE  
TALC  
TITANIUM DIOXIDE  
FERROSOFERRIC OXIDE  
POVIDONE K30  
SHELLAC  
Product Characteristics
Color WHITE Score no score
Shape CAPSULE Size 12mm
Flavor Imprint Code 54;213
Contains         
Packaging
# Item Code Package Description
1 NDC:0054-8526-25 10 CAPSULE, GELATIN COATED in 1 BLISTER PACK
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA017812 01/28/1987
Lithium CARBONATE 
Lithium carbonate capsule, gelatin coated
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0054-2526
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Lithium CARBONATE (Lithium CATION) Lithium CARBONATE 150 mg
Inactive Ingredients
Ingredient Name Strength
FD&C RED NO. 40  
GELATIN  
SODIUM LAURYL SULFATE  
TALC  
TITANIUM DIOXIDE  
FERROSOFERRIC OXIDE  
POVIDONE K30  
SHELLAC  
Product Characteristics
Color WHITE (opaque) Score no score
Shape CAPSULE Size 12mm
Flavor Imprint Code 54;213
Contains         
Packaging
# Item Code Package Description
1 NDC:0054-2526-25 100 CAPSULE, GELATIN COATED in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA017812 01/28/1987
Lithium CARBONATE 
Lithium carbonate capsule, gelatin coated
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0054-8527
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Lithium CARBONATE (Lithium CATION) Lithium CARBONATE 300 mg
Inactive Ingredients
Ingredient Name Strength
FD&C RED NO. 40  
GELATIN  
SODIUM LAURYL SULFATE  
TALC  
TITANIUM DIOXIDE  
FERROSOFERRIC OXIDE  
POVIDONE K30  
SHELLAC  
Product Characteristics
Color WHITE (flesh-colored) Score no score
Shape CAPSULE Size 15mm
Flavor Imprint Code 54;463
Contains         
Packaging
# Item Code Package Description
1 NDC:0054-8527-25 10 CAPSULE, GELATIN COATED in 1 BLISTER PACK
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA017812 07/28/1987
Lithium CARBONATE 
Lithium carbonate capsule, gelatin coated
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0054-2527
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Lithium CARBONATE (Lithium CATION) Lithium CARBONATE 300 mg
Inactive Ingredients
Ingredient Name Strength
FD&C RED NO. 40  
GELATIN  
SODIUM LAURYL SULFATE  
TALC  
TITANIUM DIOXIDE  
FERROSOFERRIC OXIDE  
POVIDONE K30  
SHELLAC  
Product Characteristics
Color WHITE (Flesh-colored) Score no score
Shape CAPSULE Size 15mm
Flavor Imprint Code 54;463
Contains         
Packaging
# Item Code Package Description
1 NDC:0054-2527-25 100 CAPSULE, GELATIN COATED in 1 BOTTLE
2 NDC:0054-2527-31 1000 CAPSULE, GELATIN COATED in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA017812 11/26/1980
Lithium CARBONATE 
Lithium carbonate capsule, gelatin coated
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0054-8531
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Lithium CARBONATE (Lithium CATION) Lithium CARBONATE 600 mg
Inactive Ingredients
Ingredient Name Strength
FD&C RED NO. 40  
GELATIN  
SODIUM LAURYL SULFATE  
TALC  
TITANIUM DIOXIDE  
FERROSOFERRIC OXIDE  
POVIDONE K30  
SHELLAC  
Product Characteristics
Color WHITE (opaque/ flesh-colored) Score no score
Shape CAPSULE Size 18mm
Flavor Imprint Code 54;702
Contains         
Packaging
# Item Code Package Description
1 NDC:0054-8531-25 10 CAPSULE, GELATIN COATED in 1 BLISTER PACK
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA017812 01/28/1987
Lithium CARBONATE 
Lithium carbonate capsule, gelatin coated
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0054-2531
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Lithium CARBONATE (Lithium CATION) Lithium CARBONATE 600 mg
Inactive Ingredients
Ingredient Name Strength
FD&C RED NO. 40  
GELATIN  
SODIUM LAURYL SULFATE  
TALC  
TITANIUM DIOXIDE  
FERROSOFERRIC OXIDE  
POVIDONE K30  
SHELLAC  
Product Characteristics
Color WHITE (opaque/ flesh-colored) Score no score
Shape CAPSULE Size 18mm
Flavor Imprint Code 54;702
Contains         
Packaging
# Item Code Package Description
1 NDC:0054-2531-25 100 CAPSULE, GELATIN COATED in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA017812 01/28/1987
Lithium 
Lithium solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0054-8529
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Lithium CITRATE (Lithium CATION) Lithium CATION 8 meq  in 5 mL
Inactive Ingredients
Ingredient Name Strength
ANHYDROUS CITRIC ACID  
RASPBERRY  
SODIUM BENZOATE  
SORBITOL  
WATER  
Packaging
# Item Code Package Description
1 NDC:0054-8529-04 5 mL in 1 CUP, UNIT-DOSE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA018421 04/29/1982
Lithium 
Lithium solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0054-3527
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Lithium CITRATE (Lithium CATION) Lithium CATION 8 meq  in 5 mL
Inactive Ingredients
Ingredient Name Strength
ANHYDROUS CITRIC ACID  
RASPBERRY  
SODIUM BENZOATE  
SORBITOL  
WATER  
Packaging
# Item Code Package Description
1 NDC:0054-3527-63 500 mL in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA018421 04/29/1982
Labeler - Roxane Laboratories, Inc (833490464)
Registrant - Roxane Laboratories, Inc (833490464)
Establishment
Name Address ID/FEI Operations
Boehringer Ingelheim Roxane Inc 058839929 MANUFACTURE(0054-8528, 0054-4527, 0054-8526, 0054-2526, 0054-8527, 0054-2527, 0054-8531, 0054-2531, 0054-8529, 0054-3527)
Establishment
Name Address ID/FEI Operations
FMC Corporation FMC Lithium Division 124549825 API MANUFACTURE(0054-8528, 0054-4527, 0054-8526, 0054-2526, 0054-8527, 0054-2527, 0054-8531, 0054-2531, 0054-3527, 0054-8529)
Revised: 03/2014
 
Roxane Laboratories, Inc
Hide
(web2)